Bookmark
Print
Recommend
  • Home
  • About PBS/IC
    • Overview
    • Nomenclature
    • Causes
    • Diagnosis
      • Overview
      • Diagnostic flow
      • NIDDK
      • Differential diagnosis
    • Management
    • Patients
      • Patient quotes
      • Case studies
    • COB Foundation Survey
      • Overview
      • Diagnosis
      • Symptoms
      • Quality of life
      • Economic impact
    • Clinical Phenotyping
      • Background to UPOINT
      • What is UPOINT
      • UPOINT research
    • References
  • Product information
    • Overview
    • Efficacy
      • Study 1
      • Study 2
    • Tolerability
    • Volume
    • Optimum dose of chondroitin sulfate
    • Budget impact
    • Mode of Action
    • Rationale for using chondroitin sulfate for PBS/IC
      • Importance of bladder GAG layer
      • Importance of chondroitin sulfate in bladder wall GAG layer
      • Dr Hurst Presentation video
    • How to administer Uracyst
    • Recommended treatment plan
    • References
  • Resources
  • KOL webcast
  • Prescribing information & adverse incident reporting
  • Request a call back

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Dr Nickel
Interview

Click here
to watch the
interview in full

MOA
Animation

Watch the
mode of action video now

           Email
           updates

Sign up today and receive regular website updates

Where am I: Product information > Recommended treatment plan

Recommended treatment plan

  • Intravesical instillation of Uracyst should be carried out weekly for four to six weeks, then monthly thereafter
  • The time to symptom resolution may vary, but optimum response is usually seen within four to six months
  • If a patient experiences any flare-up of their PBS/IC symptoms while on monthly therapy, they should revert to weekly therapy until such time that the symptoms have subsided, then go back to monthly treatments
More frequent therapy i.e. twice weekly instillations for six weeks, and then monthly thereafter for one year may be required in patients with severe PBS/IC

Home | About PBS/IC | Product information | Resources | KOL webcast | Prescribing information & adverse incident reporting | Request a call back | Contact us | Privacy | Sitemap | Copyright